Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Mol Cancer Res. 2021 Apr 16;19(7):1137–1145. doi: 10.1158/1541-7786.MCR-21-0099

Figure 1: DMAPT blocks castration mediated NF-κB and AR-V7 upregulation in VCaP-CR cells.

Figure 1:

(A) Western blot targeting NF-κB VCaP-CR cells and Enzalutamide-resistant VCaP-CR cells treated +/− DMAPT (5μM) for 72 hours. (B) Kaplan-Meier curve (time until tumor sizes > 1cm3) of VCaP-CR xenograft tumors treated with DMAPT, castration, DMAPT + castration or vehicle control (n = 6–8 mice per group). (C) Ki-67, phos-p65, AR-V7 and AR IHC staining (scale bar 25 μm) and (D) quantification in VCaP-CR xenograft tumours at ethical endpoint (n = 6–8 mice per group, error bars +/−1SEM). (E) mRNA expression of AR-FL and AR-V7 in VCaP-CR xenograft tumors treated with DMAPT, castration, DMAPT + castration or vehicle control (n = 6–8 mice per group, error bars +/−1SEM). (F) AR-V7 and Cell cycle enrichment scores from RNA-seq of VCaP-CR xenograft tumors (n = 5 mice per group). * p<0.05, **p<0.01, ***p<0.001.